A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)

被引:0
|
作者
Yao, Wanru [1 ]
Ai, Di [1 ]
Zhang, Qing [2 ]
Li, Xiaojing [3 ]
Zhou, Min [2 ]
Zhang, Ningning [4 ]
Yang, Sheng [5 ]
Chen, Zhenping [6 ]
Zhen, Yingzi [1 ]
Luke, Koon-Hung [7 ,8 ]
Wu, Runhui [1 ,9 ]
机构
[1] Capital Med Univ, Key Lab Major Dis Children,Minist Educ,Beijing Chi, Natl Ctr Childrens Hlth,Natl Key Discipline Pediat, Hematol Dept,Beijing Key Lab Pediat Hematol Oncol, Beijing, Peoples R China
[2] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Haemophilia Diag & Treatment Ctr,Dept Hematol & On, Chengdu, Peoples R China
[3] New Century Womens & Childrens Hosp, Dept Pediat, Hemophilia Treatment Ctr, Chengdu, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Radiol, Beijing, Peoples R China
[5] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Ultrasound, Chengdu, Peoples R China
[6] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Hematol Dis Lab, Beijing, Peoples R China
[7] Univ Ottawa, Children Hosp Eastern Ontario, Div Hematol & Oncol, Dept Pediat,Lab Med & Pathol, Ottawa, ON, Canada
[8] Univ Ottawa, Childrens Hosp Eastern Ontario CHEO, Dept Pediat, Div Hematol & Oncol, Ottawa, ON, Canada
[9] Capital Med Univ, Beijing Childrens Hosp, Hematol Ctr, Natl Ctr Childrens Hlth, Beijing 100045, Peoples R China
关键词
Haemophilia A; Individualized prophylaxis; Bleeding; China; Haemarthrosis; ARTHROPATHY; CHILDREN; LIFE;
D O I
10.1016/j.thromres.2024.109110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.<br /> Methods: Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.<br /> Results: A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3-6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 f 2.8 to 1.7 f 0.4 (p < 0.001), annual joint bleeding rates from 3.1 f 0.7 to1.2 f 0.3 (p < 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20-25 lU/kg, every other day), 10 at step 3 (15-20 IU/kg, 3x/week), 2 at step 2 (10-15 lU/kg, 3x/week) and 1 at step 1 (10-15 lU/kg, 2x/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.<br /> Conclusion: Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low-dose secondary prophylaxis study
    Wu, Runhui
    Li, Xiaojing
    Yao, Wanru
    Zhang, Qing
    Zhou, Min
    Zhang, Ningning
    Yang, Sheng
    Chen, Zhenping
    Wang, Yan
    Kuang, Yangying
    Tang, Ling
    Zhen, Yingzi
    Abad, Audrey
    Doria, Andrea S.
    Hilliard, Pamela
    Ignas, Danial M.
    Mathew, Prasad
    Stephens, Derek
    Blanchette, Victor S.
    Luke, Koon-Hung
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (06)
  • [32] A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B
    Rampotas, Alexandros
    Desborough, Michael J. R.
    Raza-Burton, Sayma
    Taylor, Stephanie
    Wilkinson, Alice
    Hall, Georgina W.
    Shapiro, Susan
    Curry, Nicola
    HAEMOPHILIA, 2020, 26 (02) : 278 - 281
  • [33] Cost of factor concentrates for low dose prophylaxis in severe phenotype haemophilia A under national health security office schemes in Thailand
    Pongtanakul, Bunchoo
    Narkbunnam, Nattee
    HAEMOPHILIA, 2024, 30 : 71 - 72
  • [34] Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A
    Tiede, Andreas
    Hampton, Kingsley
    Jimenez-Yuste, Victor
    Young, Guy
    El Fegoun, Soraya Benchikh
    Chowdary, Pratima
    HAEMOPHILIA, 2022, 28 (01) : 27 - 35
  • [35] Low dose prophylaxis is effective in reduction of annual bleed rates in children with severe haemophilia in India - a multi-centre study
    Apte, Shashikant
    Ross, Cecil
    Fouzia, N. A.
    Kannan, Subramaniam
    Joshi, Aditi
    Kehedekar, Dipti
    Vemula, Alekya
    Kavitha, M. L.
    Abraham, Aby
    Mannucci, Pier M.
    Calazzani, Gabriele
    HAEMOPHILIA, 2020, 26 : 66 - 66
  • [36] USING COMPREHENSIVE EVALUATION SYSTEM TO IMPLEMENT INDIVIDUALIZED PROPHYLAXIS IN YOUNG BOYS WITH HEMOPHILIA A IN CHINA:LONG-TERM CLINICAL DATA ANALYSIS OF CHIPS STUDY
    Ai, D.
    Yao, W. Y.
    Zhang, Q.
    Zhou, M.
    Li, X.
    Chen, Z.
    Wu, R.
    HAEMOPHILIA, 2023, 29 : 40 - 40
  • [37] Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
    Kessakorn, Nuchanun
    Gosriwatana, Itsaraet
    Sasipong, Nuttarak
    Srichumpuang, Chonlatis
    Moonla, Chatphatai
    Sosothikul, Darintr
    HAEMOPHILIA, 2025, 31 (01) : 122 - 131
  • [38] A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country
    Verma, S. P.
    Dutta, T. K.
    Mahadevan, S.
    Nalini, P.
    Basu, D.
    Biswal, N.
    Ramesh, A.
    Charles, D.
    Vinod, K. V.
    Kumar, K. T. Harichandra
    HAEMOPHILIA, 2016, 22 (03) : 342 - 348
  • [39] Life-long prophylaxis in a large cohort of adult patients with severe haemophilia shows a beneficial effect on ortopaedic outcomes and quality of life
    Khawaji, M.
    Astermark, J.
    Berntorp, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 746 - 746
  • [40] Discontinuing early prophylaxis in young adults with severe haemophilia A: deterioration of joint status after 10 years despite low bleeding rates
    Nijdam, A.
    Foppen, W.
    de Kleijn, P.
    Mauser-Bunschoten, E.
    Roosendaal, G.
    Van Galen, K.
    Schutgens, R.
    Fischer, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 132 - 133